Skip to main content

Table 7 WOMAC, activity and mood scores (higher scores indicate more impairment: scaled from 0 to 100 except for knee circumference).

From: S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial. [ISRCTN36233495]

   Baseline SAMe Celecoxib  
Variable N+ Mean (SD) Mean (SD) Mean (SD) Stdif.
WOMAC Knee Assessment
Tenderness 50 29.9 (21.8) 14.7* (17.4) 19.3* (18.9) 0.21
Swelling 51 15.7 (15.6) 9.8* (14.6) 8.2* (12.2) -0.11
Fluid 49 6.6 (14.1) 6.8 (14.8) 4.4 (10.1) -0.14
Knee Circumference (cm)
Total 50 41.6 (4.8) 41.5 (4.7) 42.1 (5.0) 0.52**
Above patella 50 45.0 (6.0) 44.8 (5.7) 45.4 (5.7) 0.43**
Below patella 50 38.3 (3.7) 38.2 (3.8) 38.9* (4.5) 0.40**
WOMAC Pain Frequency
Mild 49 73.3 (27.9) 57.1* (28.4) 61.2* (27.0) 0.12
Moderate 46 65.6 (19.4) 46.2* (25.8) 38.6* (24.6) -0.24
Severe 46 45.7 (20.8) 26.6* (22.6) 22.8* (24.1) -0.14
WOMAC Other
Pain – Walking 25 37.8 (31.3) 17.6* (20.5) 19.2* (22.7) 0.07
ADL 50 26.0 (13.0) 20.3* (14.2) 17.8* (15.2) -0.19
Activity Score 53 55.6 (24.3) 37.0* (27.4) 34.8* (30.0) -0.10
Mood Score 52 13.2 (14.8) 8.6* (11.8) 9.9* (12.2) 0.17
  1. Stdif: Standardized difference scores – positive numbers indicate a better response with SAMe. +Sample sizes are less than 57 due to missing data in either Phase 1 or Phase 2. *Difference between baseline and treatment is statistically significant (p < 0.05). ** Difference between SAMe and Celecoxib is statistically significant (p < 0.05).